dual-probe in situ hybridization assays may at least in part be responsible for the counterintuitive reported benefit of trastuzumab for patients with an allegedly HER2-negative tumor. Increased gene dosage (>6 HER2 gene copies or a HER2/CEP17 ratio > 2.2), regardless of the evaluation method, is however positively correlated with HER2 protein expression (P < .01, r s = 0.56 and 0.64, respectively) (6). Future prospective clinical trials should assess chromosome 17 status using methods other than or in addition to CEP17 and HER2 gene copy number to help elucidate the mechanism by which CEP17 or other pericentromeric chromosome 17 genes could possibly influence trastuzumab and lapatinib sensitivity.
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